Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke

Bruce Ovbiagele, Lee H. Schwamm, Eric E. Smith, Adrian F. Hernandez, Daiwai M. Olson, Wenqin Pan, Gregg C. Fonarow, Jeffrey L. Saver

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background and purpose: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed statins reduce vascular risk among patients with atherosclerotic stroke or transient ischemic attack. In this study, we assessed recent nationwide trends in discharge statin treatment after acute stroke and the influence of SPARCL on clinical practice. Methods: Using data from eligible patients with stroke and transient ischemic attack admitted to Get With The Guidelines-Stroke (GWTG-Stroke)-participating hospitals between January 1, 2005, and December 31, 2007, we assessed discharge statin use over time and in relation to dissemination of the SPARCL results. Results: Among 173 284 patients with ischemic stroke and transient ischemic attack, overall discharge statin treatment was 83.5%. Discharge statin prescription climbed steadily but modestly over the 2-year study period from 75.7% to 84.8% (P<0.001) with a nonsignificant increase during SPARCL reporting but a return to prior levels thereafter. Factors associated with lower discharge statin use in patients without contraindications included female sex and South region. Conclusions: Discharge statin prescription among hospitalized patients with stroke increased over time, but 1 in 5 patients still leaves the hospital without treatment. Primary drivers of increased use were secular trends and individual/hospital site characteristics.

Original languageEnglish (US)
Pages (from-to)1508-1513
Number of pages6
JournalStroke
Volume41
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stroke
Transient Ischemic Attack
Cholesterol
Therapeutics
Prescriptions
Blood Vessels
Guidelines

Keywords

  • clinical trials
  • GWTG
  • health services
  • practice patterns
  • prevention
  • statins
  • stroke
  • transient ischemic attack
  • utilization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing
  • Medicine(all)

Cite this

Ovbiagele, B., Schwamm, L. H., Smith, E. E., Hernandez, A. F., Olson, D. M., Pan, W., ... Saver, J. L. (2010). Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke, 41(7), 1508-1513. https://doi.org/10.1161/STROKEAHA.109.573618

Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. / Ovbiagele, Bruce; Schwamm, Lee H.; Smith, Eric E.; Hernandez, Adrian F.; Olson, Daiwai M.; Pan, Wenqin; Fonarow, Gregg C.; Saver, Jeffrey L.

In: Stroke, Vol. 41, No. 7, 07.2010, p. 1508-1513.

Research output: Contribution to journalArticle

Ovbiagele, B, Schwamm, LH, Smith, EE, Hernandez, AF, Olson, DM, Pan, W, Fonarow, GC & Saver, JL 2010, 'Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke', Stroke, vol. 41, no. 7, pp. 1508-1513. https://doi.org/10.1161/STROKEAHA.109.573618
Ovbiagele, Bruce ; Schwamm, Lee H. ; Smith, Eric E. ; Hernandez, Adrian F. ; Olson, Daiwai M. ; Pan, Wenqin ; Fonarow, Gregg C. ; Saver, Jeffrey L. / Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. In: Stroke. 2010 ; Vol. 41, No. 7. pp. 1508-1513.
@article{94303ade7c814669956719ef1e2a90c4,
title = "Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke",
abstract = "Background and purpose: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed statins reduce vascular risk among patients with atherosclerotic stroke or transient ischemic attack. In this study, we assessed recent nationwide trends in discharge statin treatment after acute stroke and the influence of SPARCL on clinical practice. Methods: Using data from eligible patients with stroke and transient ischemic attack admitted to Get With The Guidelines-Stroke (GWTG-Stroke)-participating hospitals between January 1, 2005, and December 31, 2007, we assessed discharge statin use over time and in relation to dissemination of the SPARCL results. Results: Among 173 284 patients with ischemic stroke and transient ischemic attack, overall discharge statin treatment was 83.5{\%}. Discharge statin prescription climbed steadily but modestly over the 2-year study period from 75.7{\%} to 84.8{\%} (P<0.001) with a nonsignificant increase during SPARCL reporting but a return to prior levels thereafter. Factors associated with lower discharge statin use in patients without contraindications included female sex and South region. Conclusions: Discharge statin prescription among hospitalized patients with stroke increased over time, but 1 in 5 patients still leaves the hospital without treatment. Primary drivers of increased use were secular trends and individual/hospital site characteristics.",
keywords = "clinical trials, GWTG, health services, practice patterns, prevention, statins, stroke, transient ischemic attack, utilization",
author = "Bruce Ovbiagele and Schwamm, {Lee H.} and Smith, {Eric E.} and Hernandez, {Adrian F.} and Olson, {Daiwai M.} and Wenqin Pan and Fonarow, {Gregg C.} and Saver, {Jeffrey L.}",
year = "2010",
month = "7",
doi = "10.1161/STROKEAHA.109.573618",
language = "English (US)",
volume = "41",
pages = "1508--1513",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke

AU - Ovbiagele, Bruce

AU - Schwamm, Lee H.

AU - Smith, Eric E.

AU - Hernandez, Adrian F.

AU - Olson, Daiwai M.

AU - Pan, Wenqin

AU - Fonarow, Gregg C.

AU - Saver, Jeffrey L.

PY - 2010/7

Y1 - 2010/7

N2 - Background and purpose: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed statins reduce vascular risk among patients with atherosclerotic stroke or transient ischemic attack. In this study, we assessed recent nationwide trends in discharge statin treatment after acute stroke and the influence of SPARCL on clinical practice. Methods: Using data from eligible patients with stroke and transient ischemic attack admitted to Get With The Guidelines-Stroke (GWTG-Stroke)-participating hospitals between January 1, 2005, and December 31, 2007, we assessed discharge statin use over time and in relation to dissemination of the SPARCL results. Results: Among 173 284 patients with ischemic stroke and transient ischemic attack, overall discharge statin treatment was 83.5%. Discharge statin prescription climbed steadily but modestly over the 2-year study period from 75.7% to 84.8% (P<0.001) with a nonsignificant increase during SPARCL reporting but a return to prior levels thereafter. Factors associated with lower discharge statin use in patients without contraindications included female sex and South region. Conclusions: Discharge statin prescription among hospitalized patients with stroke increased over time, but 1 in 5 patients still leaves the hospital without treatment. Primary drivers of increased use were secular trends and individual/hospital site characteristics.

AB - Background and purpose: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed statins reduce vascular risk among patients with atherosclerotic stroke or transient ischemic attack. In this study, we assessed recent nationwide trends in discharge statin treatment after acute stroke and the influence of SPARCL on clinical practice. Methods: Using data from eligible patients with stroke and transient ischemic attack admitted to Get With The Guidelines-Stroke (GWTG-Stroke)-participating hospitals between January 1, 2005, and December 31, 2007, we assessed discharge statin use over time and in relation to dissemination of the SPARCL results. Results: Among 173 284 patients with ischemic stroke and transient ischemic attack, overall discharge statin treatment was 83.5%. Discharge statin prescription climbed steadily but modestly over the 2-year study period from 75.7% to 84.8% (P<0.001) with a nonsignificant increase during SPARCL reporting but a return to prior levels thereafter. Factors associated with lower discharge statin use in patients without contraindications included female sex and South region. Conclusions: Discharge statin prescription among hospitalized patients with stroke increased over time, but 1 in 5 patients still leaves the hospital without treatment. Primary drivers of increased use were secular trends and individual/hospital site characteristics.

KW - clinical trials

KW - GWTG

KW - health services

KW - practice patterns

KW - prevention

KW - statins

KW - stroke

KW - transient ischemic attack

KW - utilization

UR - http://www.scopus.com/inward/record.url?scp=77954177559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954177559&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.109.573618

DO - 10.1161/STROKEAHA.109.573618

M3 - Article

C2 - 20508182

AN - SCOPUS:77954177559

VL - 41

SP - 1508

EP - 1513

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 7

ER -